| Description |
LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC50 of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC50 of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines[1].
|
| Related Catalog |
|
| Target |
IC50: 24.43 ± 1.08 nM (LSD1), 5.00 ± 0.28 μM (LSD2), >100 μM (MAO-A), >100 μM (MAO-B)[1]
|
| In Vitro |
LSD1-IN-13 (compound 7e) shows good selectivity over LSD2 (205-fold) and MAOs (>4000-fold)[1]. LSD1-IN-13 shows potent and selective antiproliferative activity in MV-4-11, with an IC50 of 1.36 μM[1].
|
| In Vivo |
LSD1-IN-13 (compound 7e) (MV-4-11 xenograft mice, 0-20 mg/kg, Orally, daily for 15 days) suppresses tumor growth significantly in a dose-dependent manner[1].
|
| References |
[1]. Li C, et al. Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors. J Med Chem. 2022 Mar 10;65(5):4335-4349.
|
